Ardelyx (NASDAQ:ARDX) Hits New 1-Year Low – What’s Next?

Ardelyx, Inc. (NASDAQ:ARDX)’s share price hit a new 52-week low during trading on Monday. The company traded as low as $3.18 and last traded at $3.2350, with a volume of 300,422 shares changing hands. The stock had previously closed at $3.28.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Positive clinical-commercial data: Ardelyx presented real-world data at the American College of Gastroenterology 2026 meeting showing significantly reduced gastrointestinal healthcare-resource utilization after adults with IBS-C began treatment with IBSRELA (tenapanor). The findings could support the drug’s value proposition with physicians and payers. Ardelyx ACG 2026 IBSRELA data
• Neutral Sentiment: Investor deadline reiterated: Rosen, Levi & Korsinsky, Faruqi & Faruqi, Kaplan Fox, SBS, Pomerantz and other firms are soliciting investors who purchased ARDX shares from January 13, 2025, through August 6, 2026, to seek lead-plaintiff status by November 16. These releases are primarily legal-firm notices and do not establish wrongdoing. Rosen Ardelyx investor notice
• Negative Sentiment: Alleged payer-access issues: The lawsuit claims Ardelyx management provided overly reassuring statements about patient access while prior-authorization and step-edit requirements allegedly restricted IBSRELA and XPHOZAH prescriptions. The filings connect the claims to an approximately 18% share-price decline following the August 6 guidance announcement, increasing uncertainty around commercial execution and potential legal costs. ARDX shareholder lawsuit alert

Analyst Ratings Changes

ARDX has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Ardelyx in a research note on Friday, August 7th. Citigroup lowered their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th. TD Cowen lowered their price objective on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Zacks Research cut shares of Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ardelyx in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.90.

Ardelyx Stock Performance

The firm has a 50 day moving average price of $3.68 and a 200-day moving average price of $5.06. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%. The company had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. The company’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, analysts anticipate that Ardelyx, Inc. will post -0.20 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Eric Foster sold 8,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the sale, the insider owned 409,410 shares of the company’s stock, valued at $1,580,322.60. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Laura A. Williams sold 10,739 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $41,452.54. Following the completion of the sale, the insider directly owned 367,456 shares in the company, valued at approximately $1,418,380.16. This trade represents a 2.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 126,059 shares of company stock worth $486,588. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Ardelyx in the 2nd quarter valued at about $35,000. SCS Capital Management LLC purchased a new stake in Ardelyx during the second quarter worth approximately $52,000. ADAR1 Capital Management LLC acquired a new position in Ardelyx in the second quarter valued at approximately $56,000. PVG Asset Management Corp acquired a new position in Ardelyx in the first quarter valued at approximately $65,000. Finally, Krilogy Financial LLC acquired a new position in Ardelyx in the first quarter valued at approximately $70,000. 58.92% of the stock is owned by hedge funds and other institutional investors.

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s products are designed to act locally in the gastrointestinal tract to address diseases involving phosphate, sodium, and other electrolytes.

Ardelyx’s primary products include XPHOZAH (tenapanor), an oral treatment approved in the United States to reduce intestinal phosphate absorption in adults with chronic kidney disease on dialysis who have hyperphosphatemia, and IBSRELA (tenapanor), an oral therapy approved for the treatment of irritable bowel syndrome with constipation in adults.